To investigate the diagnostic performance of early acquisition compared to late imaging for the detection of local recurrence of prostate cancer by means of (18)F-FCH PET/CT.
FREE DAILY AND WEEKLY NEWSLETTERS OFFERED BY CONTENT OF INTEREST
Did you find this article relevant? Subscribe to UroToday-GUOncToday!
The fields of GU Oncology and Urology are advancing rapidly including new treatments, enrolling clinical trials, screening and surveillance recommendations along with updated guidelines. Join us as one of our subscribers who rely on UroToday as their must-read source for the latest news and data on drugs. Sign up today for blogs, video conversations, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.
99 patients with radical prostatectomy (mean PSA 3.
9 ± 5 03) were subjected to early dynamic PET/CT acquisition of the pelvis and a whole body PET/CT in the same exam session. None of the patients examined was subjected to radiotherapy for local or distant recurrence All the subjects were taken off hormonal therapy.
58 subjects did not show local recurrence in both early and late acquisition, 22 were positive in both modalities, 10 showed a positive early and a negative late acquisition while 9 showed a negative early and a positive late acquisition (Cohen's k = 0.558). When the results of imaging modalities were considered separately, sensitivity, specificity, positive predictive value and negative predictive value resulted: 78.9, 96.7, 93.8 and 88.1 % for early acquisition and 73.7, 95.1, 90.3 and 85.3 % for late acquisition, respectively. When the results of early and late acquisition were considered together, results were 97.4, 93.4, 90.2 and 98.3 %, respectively.
The combination of early acquisition with late acquisition lead to an increase of the diagnostic accuracy of (18)F-FCH PET/CT for the diagnosis of local recurrence in prostate cancer.
Annals of nuclear medicine 2015 Aug 11 [Epub ahead of print]
Daniele Di Biagio, Agostino Chiaravalloti, Mario Tavolozza, Paolo Abbatiello, Orazio Schillaci
Department of Biomedicine and Prevention, University Tor Vergata, viale Oxford 81, 00133, Rome, Italy